Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · IEX Real-Time Price · USD
35.55
-0.16 (-0.45%)
At close: Jul 19, 2024, 4:00 PM
35.45
-0.10 (-0.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $314.95M in the twelve months ending March 31, 2024, with 36,565.08% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $254.95M. In the year 2023, Protagonist Therapeutics had annual revenue of $60.00M with 125.73% growth.
Revenue (ttm)
$314.95M
Revenue Growth
+36,565.08%
P/S Ratio
6.62
Revenue / Employee
$2,812,080
Employees
112
Market Cap
2.09B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
Dec 31, 2017 | 20.06M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
Premier | 1.34B |
LifeStance Health Group | 1.10B |
Addus HomeCare | 1.09B |
10x Genomics | 625.45M |
Catalyst Pharmaceuticals | 411.35M |
Beam Therapeutics | 360.91M |
STAAR Surgical Company | 326.24M |
PTGX News
- 53 minutes ago - Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 - Accesswire
- 7 weeks ago - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 - Accesswire
- 2 months ago - Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event - Accesswire
- 2 months ago - Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update - Accesswire
- 4 months ago - Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data - Accesswire
- 4 months ago - Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - Accesswire
- 4 months ago - Protagonist Therapeutics to Participate in Upcoming Investor Conferences - Accesswire